Andrew Fein is a Managing Director of Equity Research at H.C. Wainwright. Mr. Fein conducted more than twelve years of biotechnology equity research. Prior to joining H.C. Wainwright, Mr. Fein worked as the Head of the Healthcare Research effort at Chardan Capital Markets. Mr. Fein began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. After that, Mr. Fein worked as a Managing Director/Senior Biotechnology Analyst at Jefferies, Piper Jaffray and Collins Stewart.
Article: H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)
Article - MediaH.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)
Jason Carr
AnalystRatings, 1 May 2020
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $52.00. The company’s shares closed last Thursday at $23.00.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 7.7% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
Article: Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright
Article - MediaVertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright
Austin Angelo
SmarterAnalyst, 30 April 2020
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
Comment: This company is at risk of collusion between a placement agent and naked short sellers.
